“Plasma exchange in a bottle”: An overview of efgartigimod for apheresis practitioners
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.22002
Abstract: Efgartigimod represents a first‐in‐class immunomodulatory agent that is comparable to TPE in reducing immunoglobulin levels. This translates to reductions in Myasthenia Gravis symptom scores with maximal effect following the fourth weekly efgartigimod dose. Efgartigimod received… read more here.
Keywords: long term; plasma exchange; apheresis; apheresis practitioners ... See more keywords
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
Sign Up to like & getrecommendations! Published in 2019 at "Neurology"
DOI: 10.1212/wnl.0000000000007600
Abstract: Objective To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were… read more here.
Keywords: myasthenia gravis; generalized myasthenia; gravis; study ... See more keywords